Back to search results

A Study of BMS-986489 for Extensive-Stage Small Cell Lung Cancer

This study is comparing two treatment approaches for extensive-stage small cell lung cancer (SCLC), which is cancer that has spread widely. You would receive either BMS-986489 (a combination of BMS-986012 and nivolumab) or atezolizumab. Both of these are given along with carboplatin and etoposide, which are standard chemotherapy drugs. The main goal is to see how long people live (Overall Survival) with each treatment, and to understand the safety of these combinations. To join, you must have extensive-stage SCLC and be healthy enough for most daily activities. The study aims to enroll 530 participants.

Study design
This is an interventional study comparing two different drug combinations. It plans to enroll 530 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for Overall Survival for up to 5 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06646276

A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

Recruiting
PHASE3Ages 18+InterventionalTreatment
Bristol-Myers Squibb
~530 participants
Updated 2026-08-14 on ClinicalTrials.gov
What's tested:BMS-986489 (BMS-986012+Nivolumab)AtezolizumabCarboplatinEtoposide

At a glance

Recruiting sites
18 of 183 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Overall Survival (OS)
Measured over Up to 5 years

Conditions

Extensive-Stage Small Cell Lung Cancer

Explore related trials

Lung Small Cell Carcinoma

Where it's being run

183 sites across 126 states
Santiago Metropolitan4
Germany4
Turkey (Türkiye)4
Florida3
Buenos Aires F.D.3
Rio Grande do Sul3
Quebec3
Shanghai Municipality3

Study leadership

  • Bristol-Myers Squibb · STUDY_DIRECTOR · Bristol-Myers Squibb

Who to contact

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
[email protected]
855-907-3286
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Participants must have diagnosis of Extensive-Stage Small Cell Lung Cancer (ES-SCLC).
Participants must be Healthy enough to do their normal activities with little or no help based on the ECOG performance scale.
Participants must have at least one tumor that can be measured using special imaging techniques like a CT scan or MRI at a site other than the brain and nervous system

Exclusion

Participants have already received certain types of treatment for extensive stage small cell lung cancer
Participants have certain health conditions, like spread of small cell lung cancer to the brain that are causing symptoms, certain lung diseases, heart diseases, infections, autoimmune diseases, other cancers, or a type of nerve damage called peripheral sensory neuropathy

What this trial measures

  • Overall Survival (OS)Up to 5 years